XML 146 R126.htm IDEA: XBRL DOCUMENT v3.25.0.1
Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net loss $ (644,786) $ (881,708) $ (2,003,815)
Adjustments to reconcile net loss to net cash used in operating activities:      
Acquired in-process research and development 60,000 46,800 68,665
Amortization of research and development cost share liability (73,226) (55,294) (96,402)
Other items, net 11,163 (5,998) 9,047
Changes in operating assets and liabilities:      
Accrued expenses and other payables 111,354 180,111 45,627
Net cash used in operating activities (140,631) (1,157,453) (1,496,619)
Cash flows from investing activities:      
Proceeds from sale or maturity of short-term investments 2,655 673,240 1,563,618
Purchase of in-process research and development (31,800) (15,000) (143,665)
Other investing activities (2,862) (2,075) (1,485)
Net cash (used in) provided by investing activities (548,350) 60,004 1,077,123
Cash flows from financing activities:      
Proceeds from short-term loans 868,270 661,530 313,774
Repayment of short-term loans (704,216) (309,576) (417,081)
Proceeds from option exercises and employee share purchase plan 45,373 55,712 46,964
Net cash provided by (used in) financing activities 193,449 416,478 (18,971)
Effect of foreign exchange rate changes, net (51,705) (8,082) (69,383)
Net decrease in cash, cash equivalents, and restricted cash (547,237) (689,053) (507,850)
Cash, cash equivalents, and restricted cash, beginning of year 3,185,984 3,875,037 4,382,887
Cash, cash equivalents, and restricted cash, end of year 2,638,747 3,185,984 3,875,037
Parent Company      
Cash flows from operating activities:      
Net loss (644,786) (881,708) (2,003,815)
Adjustments to reconcile net loss to net cash used in operating activities:      
Acquired in-process research and development 0 15,000 0
Amortization of research and development cost share liability (73,226) (55,294) (96,402)
Unrealized losses on long-term investments (85,471) 237,351 932,071
Other items, net 31,651 (374,370) (596,496)
Changes in operating assets and liabilities:      
Prepaid expenses and other current assets 1,053 30,519 6,671
Accrued expenses and other payables 627,307 (140,126) 875,826
Net cash used in operating activities (143,472) (1,168,628) (882,145)
Cash flows from investing activities:      
Purchases of short-term investments 0 (2,075) (1,485)
Proceeds from sale or maturity of short-term investments 2,628 552,000 1,487,028
Purchase of in-process research and development 0 (15,000) (75,000)
Purchase of long-term investments (406,624) (883,328) (2,675,908)
Other investing activities (37,120) 188,656 79,004
Net cash (used in) provided by investing activities (441,116) (159,747) (1,186,361)
Cash flows from financing activities:      
Proceeds from short-term loans 813,058 547,842 296,188
Repayment of short-term loans (593,898) (293,002) (247,460)
Proceeds from option exercises and employee share purchase plan 45,371 55,712 46,965
Net cash provided by (used in) financing activities 264,531 310,552 95,693
Effect of foreign exchange rate changes, net (4,356) 0 0
Net decrease in cash, cash equivalents, and restricted cash (324,413) (1,017,823) (1,972,813)
Cash, cash equivalents, and restricted cash, beginning of year 724,548 1,742,371 3,715,184
Cash, cash equivalents, and restricted cash, end of year $ 400,135 $ 724,548 $ 1,742,371